Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Shares Are Jumping Again Today

By Keith Speights - Jan 27, 2020 at 11:03AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Increased fears about a viral outbreak are causing the biotech stock to rise even more after last week's big gains.

What happened

Shares of Novavax (NVAX 12.49%) were jumping 13.6% higher as of 11:14 a.m. EST on Monday. The big gain came after the stock skyrocketed last week as fears increased about the coronavirus outbreak in China that has spread to the U.S. Today's increase resulted from even greater worries as more U.S. cases of infection were confirmed over the weekend.

So what

Novavax ranks as one of a handful of biotechs that have programs that could potentially address the coronavirus strain that's causing such alarm. The company announced last week that it's working to develop a vaccine for the virus.

Gloved hand holding a vial of blood with a label stating "coronavirus"

Image source: Getty Images.

But while Novavax and other antivirus-focused biotech stocks are benefiting from the increased concerns, it's important for investors to remember that none of these companies have a product that can target the coronavirus strain right now. Novavax president of research and development Greg Glenn was exactly right when he said in an interview with Yahoo! Finance last week that it could take a long time before an effective and safe vaccine is ready.

Now what

Investors definitely should keep their eyes on Novavax's progress toward developing a vaccine that could address the coronavirus strain that is making headlines. They should also watch the progress of other drugmakers, including BioCryst Pharmaceuticals, Inovio, Moderna, Gilead Sciences, and Johnson & Johnson.

However, the primary potential catalyst for Novavax in the near future is the company's results from a late-stage clinical study of its NanoFlu flu vaccine expected to be announced later in the first quarter of 2020. If those results are positive, the company could be on track to get its first approved therapy on the market.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$64.29 (12.49%) $7.14
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$178.14 (-0.77%) $-1.38
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$62.34 (-0.03%) $0.02
BioCryst Pharmaceuticals, Inc. Stock Quote
BioCryst Pharmaceuticals, Inc.
BCRX
$11.14 (2.77%) $0.30
Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$2.07 (9.52%) $0.18
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$155.54 (3.73%) $5.59

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.